Curetis
Molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€26—40m (Dealroom.co estimates May 2019.)
Company register number 64302679
Holzgerlingen Baden-Württemberg (HQ)
Financials
Estimates*
| USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 2.2m | 2.2m | 1.1m | 1.1m | 5.5m | - |
| % growth | - | - | (50 %) | - | 400 % | - |
| EBITDA | - | - | (18.7m) | (24.2m) | (12.1m) | 1.1m |
| % EBITDA margin | - | - | (1700 %) | (2200 %) | (220 %) | - |
| Profit | - | - | (19.0m) | - | - | - |
| % profit margin | - | - | (1727 %) | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€14.5m | Series B | ||
| N/A | €40.0m Valuation: €151m | IPO | |
| N/A | €20.0m | Post IPO Debt | |
$7.3m | Early VC | ||
* | N/A | Acquisition | |
| Total Funding | €55.2m | ||
Related Content
Recent News about Curetis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
